Biocon Knocked Back By FDA On Human Insulin
Biosimilar Filing Receives CRL Citing Need For More Data And Facility Remediation
Biocon has seen its insulin-R application knocked back by the US FDA, with a complete response letter citing a need for more data as well as the need for remediation activities at its Bangalore facilities.
